We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.

A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored.

The Phase 1 trial is an open label, dose ranging clinical study designed to evaluate Vaxart’s second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.

The Phase 2b ICONA clinical trial was a 52-week randomized, double-blind, placebo-controlled trial that evaluated the safety and histological impact of icosabutate at 300 and 600 mg compared to ...

In a regulatory filing, BioNTech (BNTX) disclosed that the U.S. Food and Drug Administration has informed BioNTech SE that it has placed a ...